CXCR4 and B-cell chronic lymphocytic leukemia: Moreover, ibrutinib is known to inhibit CXCR4-mediated expression of CD20 in CLL cells50, which could have implications for clinical trials combining ibrutinib and anti-CD20 antibodies (e.g., NCT02007044).